CTT Pharmaceutical auditor agrees with disclosure

CTT Pharmaceutical Holdings, Inc. says it is submitting a response letter from the auditor associated with its prior Form 8-K. The auditor agrees with what the company previously filed.

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. says it is submitting a response letter from the auditor associated with its prior Form 8-K. The auditor agrees with what the company previously filed.

8-K Event Classification

2 items: 4.01, 9.01

2 items

Item 4.01 Changes in Registrant's Certifying Accountant Governance

The company changed its independent auditing firm, which may involve disagreements on accounting matters.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

certifying accountant, Interactive Data File, Inline XBRL

3 terms

certifying accountant regulatory

"Changes in Registrant’s Certifying Accountant"

Interactive Data File technical

"Cover Page Interactive Data File"

Inline XBRL technical

"embedded within the Inline XBRL document"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the auditor say about CTT Pharmaceutical Holdings (CTTH)'s prior 8-K?

The auditor said it agrees with what CTT Pharmaceutical Holdings previously filed. The company is submitting the auditor’s response as a letter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/09/2026 - 04:14 PM EDT Accepted by SEC EDGAR 10/09/2026 - 04:13 PM EDT Learn about SEC filing dates

0001035422false00010354222026-10-082026-10-08iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 8, 2026

CTT PHARMACEUTICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Florida		333-292497		90-1253984
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1646 W Snow Ave. Suite 138 Tampa, FL. 33606

(Address of Principal Executive Offices) (Zip Code)

813-606-0060

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01 Changes in Registrant’s Certifying Accountant.

CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is filing a response from the auditor of our last 8-K. The auditor agrees to what CTT Pharma previously filed. 

Item 9.01 Financial Statements and Exhibits.

(b) Exhibits

Exhibit		Description
16.1		Letter
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CTT PHARMACEUTICAL HOLDINGS, INC.
		(Registrant)
Date: 10/09/2026		By:	/s/ Ryan Khouri
		Name:	Ryan Khouri
		Title:	Chief Executive Officer (Principal Executive, Financial and Accounting Officer)

3

Filing Exhibits & Attachments

6 documents

Other Documents

• EX-16.1 LETTER 3.4 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 12.9 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 8.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB